Papatheodoridi M. Rates and predictors of HBsAg loss after discontinuation of effective long-term Entecavir or Tenofovir therapy in non-cirrhotic HBeAg-negative Chronic Hepatitis B patients: Results from the DARING-B prospective Greek study. PS-159.
Ernstige bijwerkingen (hydroxy)chloroquine bij malaria en reuma zeldzaam
jan 2024 | Parasitaire infecties, RA, Virale infecties